Most addressing unmet market needs. Some with platform drugs. A lot with ODD and PRV approvals.
Lots with equal or greater future earnings potential either from one drug, platform drug or multiple different drugs in their pipeline.
The tax incentive re research in Australia means lots of early drug development is done here.
Australia punches well above its weight in drug discovery biotechnology companies and research.
RAC - Charts & Price Action, page-18184
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.055(3.79%) |
Mkt cap ! $237.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.33 | $213.7K | 155.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7167 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |